Ohr Pharmaceutical is engaged in the development of novel therapeutics for the treatment of serious and unmet medical needs. The company’s lead compounds include OHR/AVR 118 for the treatment of cancer cachexia, and Squalamine eye drops for the treatment of the wet form of age-related macular degeneration and other ophthalmic neovascularization disorders. For further information, visit the company’s Web site at www.ohrpharmaceutical.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: